Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS Device Engineering Novel technologies for implanting and protecting cell replacement therapies We have two types of proprietary medical devices to contain, protect, and implant our cell replacement therapies. They differ based on whether they are immune-protective or allow direct vascularization. In addition, each type of device has multiple different sizes available for both preclinical and/or clinical use. Sentinels provide a window for clinical research ViaCyte is using two sizes of devices for clinical trials; a larger device designed for determining a therapeutic dose of cells and a smaller clinical research device, called a “sentinel.” Sentinels are small-format cell-filled devices that are used to evaluate safety and implant viability. These units can be removed at specific time points and examined histologically to provide early insight into the progression of engraftment and maturation of the PEC-01 cells into islet cells, including insulin-producing beta cells. Development of human cell replacement therapy requires optimization of the product candidates in patients. Evaluation in animal models provides limited information, because when the human cells are implanted in an animal, a different species, it elicits an immune response that is unlike the response that occurs when the human cells are implanted in a human patient. The sentinels provide an elegant and effective methodology for product optimization in patients. COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT

Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS FAQ (Frequently Asked Questions) Who would be eligible for the PEC-Encap™ product? Who would be eligible for the PEC-Direct™ product? How does the PEC-Direct™ product compare to islet transplants? Where and how are the product candidates implanted? Are ViaCyte product candidates considered medical devices? What is the size of the product candidate? How long will the product last? People with type 1 diabetes have autoimmunity to insulin-producing beta cells. Won’t that same autoimmunity harm or destroy the cells in ViaCyte’s product candidates? When will the product candidates be available – when can I get it from my doctor? COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT